An open-label dose-escalation study to assess the safety and bioavailability of single oral doses of azacitidine in patients with myelodysplastic syndromes (MDS), acute myelogenous leukemia (AML), or solid tumors

Trial Profile

An open-label dose-escalation study to assess the safety and bioavailability of single oral doses of azacitidine in patients with myelodysplastic syndromes (MDS), acute myelogenous leukemia (AML), or solid tumors

Completed
Phase of Trial: Phase I

Latest Information Update: 23 Apr 2007

At a glance

  • Drugs Azacitidine (Primary)
  • Indications Acute myeloid leukaemia; Myelodysplastic syndromes; Solid tumours
  • Focus Adverse reactions
  • Sponsors Pharmion Corporation
  • Most Recent Events

    • 23 Apr 2007 Status change from in recruiting to completed.
    • 15 Feb 2007 Status changed from planning to recruiting.
    • 02 Feb 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top